
Cecilia Cabrera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7153205/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment. Oncolmmunology, 2022, 11, 2051845.	2.1	3
2	Modulation of the autophagic pathway inhibits HIV-1 infection in human lymphoid tissue cultured ex vivo. Scientific Reports, 2022, 12, 7439.	1.6	4
3	The Interplay of HIV and Autophagy in Early Infection. Frontiers in Microbiology, 2021, 12, 661446.	1.5	20
4	SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients. Viruses, 2021, 13, 1715.	1.5	14
5	HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic. Scientific Reports, 2019, 9, 5544.	1.6	17
6	Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC. Oncolmmunology, 2019, 8, 1602460.	2.1	22
7	Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice. Scientific Reports, 2018, 8, 15102.	1.6	11
8	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 201-205.	0.9	7
9	Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. Scientific Reports, 2017, 7, 11711.	1.6	12
10	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS ONE, 2017, 12, e0184433.	1.1	17
11	Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes. Aids, 2016, 30, 2275-2287.	1.0	10
12	Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. Journal of Translational Medicine, 2015, 13, 230.	1.8	33
13	Transient increment of HTLV-2 proviral load in HIV-1-co-infected patients during treatment intensification with raltegravir. Journal of Clinical Virology, 2014, 59, 204-207.	1.6	3
14	Functional Analyses Reveal Extensive RRE Plasticity in Primary HIV-1 Sequences Selected under Selective Pressure. PLoS ONE, 2014, 9, e106299.	1.1	4
15	Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. Journal of Translational Medicine, 2013, 11, 68.	1.8	92
16	Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 648-658.	1.1	13
17	Evaluation of the Cytopathicity (Fusion/Hemifusion) of Patient-Derived HIV-1 Envelope Glycoproteins Comparing Two Effector Cell Lines. Journal of Biomolecular Screening, 2012, 17, 727-737.	2.6	9
18	Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function. PLoS ONE, 2012, 7, e30330.	1.1	13

CECILIA CABRERA

#	Article	IF	CITATIONS
19	The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. Retrovirology, 2012, 9, 15.	0.9	8
20	Susceptibility of Human Lymphoid Tissue Cultured ex vivo to Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Infection. PLoS ONE, 2012, 7, e37415.	1.1	2
21	On the steps of cell-to-cell HIV transmission between CD4 T cells. Retrovirology, 2009, 6, 89.	0.9	38
22	Raltegravir, an HIV-1 integrase inhibitor for HIV infection. Current Opinion in Investigational Drugs, 2008, 9, 885-98.	2.3	8
23	Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. Aids, 2006, 20, 2075-2080.	1.0	41
24	Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide. Aids, 2006, 20, 1896-1898.	1.0	4
25	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: Eurosida Study. Antiviral Therapy, 2004, 9, 787-800.	0.6	7
26	Cell-Surface-Expressed HIV-1 Envelope Induces the Death of CD4 T Cells during GP41-Mediated Hemifusion-like Events. Virology, 2003, 305, 318-329.	1.1	70
27	Anti-HIV activity of a novel aminoglycoside-arginine conjugate. Antiviral Research, 2002, 53, 1-8.	1.9	31
28	CD4+ and CD8+ T Cell Death during Human Immunodeficiency Virus Infection in Vitro. Virology, 2001, 285, 356-365.	1.1	19
29	The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. Aids, 1999, 13, 909-917.	1.0	74